FTD Companies, Inc. Common Stock

FTD

WASHINGTON--(BUSINESS WIRE)--The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) announced key resources and philanthropic capital to reshape scientific research fields and advance better diagnostics and treatments at the annual Future of Health Summit. Over the last two months, SPARC has worked with philanthropic partners to guide the strategic deployment of nearly $70 million toward neglected research fields, issue four open-access research reports, an.

LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that the first patient has been treated in the Phase 1/2 ASPIRE-FTD trial evaluating AviadoBio's investigational gene therapy, AVB-101, in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN). Clinical trial sites are currently open in Poland, Spain, and the Netherla.